In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment-Reference-Cited by-同舟云学术

In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment

Published:2018-03-16 Issue:6 Volume:73 Page:1525-1529
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:

Author:

Gaibani Paolo¹^ORCID,Campoli Caterina²,Lewis Russell E²³,Volpe Silvia Lidia¹,Scaltriti Erika⁴,Giannella Maddalena²³,Pongolini Stefano⁴,Berlingeri Andrea¹,Cristini Francesco²,Bartoletti Michele²,Tedeschi Sara²,Ambretti Simone¹

Affiliation:

1. Operative Unit of Clinical Microbiology, S. Orsola-Malpighi University Hospital, Bologna, Italy

2. Operative Unit of Infectious Diseases, S. Orsola-Malpighi University Hospital, Bologna, Italy

3. Department of Medical and Surgical Sciences DIMEC, University of Bologna, Bologna, Italy

4. Risk Analysis Unit, Istituto Zooprofilattico Sperimentale della Lombardia e dell’Emilia Romagna (IZSLER), Parma, Italy

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Link

http://academic.oup.com/jac/article-pdf/73/6/1525/24804875/dky082.pdf

Reference20 articles.

1. Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance;Pitout;Antimicrob Agents Chemother,2015

2. The β-lactams strike back: ceftazidime-avibactam;Zasowski;Pharmacotherapy,2015

3. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms;Temkin;Antimicrob Agents Chemother,2017

4. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections;Shields;Clin Infect Dis,2016

5. Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum β-lactamases;Haidar;Antimicrob Agents Chemother,2017

Cited by 138 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reversion of KPC-114 to KPC-2 in ceftazidime-avibactam- resistant/meropenem-susceptible Klebsiella pneumoniae ST11 is related to low mutation rates;Microbiology Spectrum;2024-08-27

2. An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in critically ill patients;Journal of Antimicrobial Chemotherapy;2024-08-19

3. A large-scale surveillance revealed that KPC variants mediated ceftazidime-avibactam resistance in clinically isolated Klebsiella pneumoniae;Microbiology Spectrum;2024-08-06

4. Mecanismos moleculares y epidemiología de la resistencia a ceftazidima-avibactam: un análisis integral;Acta Pediátrica de México;2024-07-25

5. Ceftazidime-Avibactam as a Salvage Treatment for Severely Infected Immunosuppressed Children;Drug Design, Development and Therapy;2024-07